Quantum Genomics Corp. Gets 1 Million $ (740 K€) From Oseo to Finance the Regulatory Preclinical Development of QGC 001

MASSY, France--(BUSINESS WIRE)--Quantum Genomics SAS, a privately held company, announced today that it has received a Research financing (Aide à l’Innovation) worth 1 million dollars from the French agency Oseo, to perform a preclinical evaluation of QGC 001, the first drug to treat hypertension by targeting Aminopeptidase A, and has initiated the preclinical studies required for the submission of an Investigational Medicinal Product Dossier (IMPD). “The program is following initial development plan, thanks to our partners involved in the project” comments Jean Pierre Riffaud, Head of preclinical development at Quantum Genomics.